Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Omeros Corporation patents


Recent patent applications related to Omeros Corporation. Omeros Corporation is listed as an Agent/Assignee. Note: Omeros Corporation may have other listings under different names/spellings. We're not affiliated with Omeros Corporation, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "O" | Omeros Corporation-related inventors


Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods

The present invention relates to stable, high-concentration low-viscosity formulations of masp-2 inhibitory antibodies, kits comprising the formulations and therapeutic methods using the formulations and kits for inhibiting the adverse effects of masp-2 dependent complement activation.. . ... Omeros Corporation

Pde10 inhibitors and related compositions and methods

Compounds that inhibit pde10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as parkinson's disease, huntington's disease, alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, bell's palsy, cerebral palsy, sleep disorders, pain, tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided. ... Omeros Corporation

Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy

In one aspect, the invention provides methods for reducing proteinuria in a human subject suffering, or at risk of developing immunoglobulin a nephropathy (igan). The methods comprise the step of administering, to a subject in need thereof, an amount of a masp-2 inhibitory antibody effective to inhibit masp-2-dependent complement activation.. ... Omeros Corporation

Stable preservative-free mydriatic and anti-inflammatory solutions for injection

The present invention relates to stable, preservative- and antioxidant-free liquid formulations of phenylephrine and ketorolac for injection.. . ... Omeros Corporation

Processes and intermediates for the preparation of a pde10 inhibitor

The present invention is directed to an improved process for the preparation of compounds of formula (ii) and formula (iii), which are useful in the inhibition of pde10. In particular, the present invention is directed to an improved process for the preparation of 1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, which is useful in the inhibition of pde10.. ... Omeros Corporation

Monoclonal antibodies, compositions and methods for detecting mucin-like protein (mlp) as a biomarker for ovarian and pancreatic cancer

In various embodiments the invention provides anti-mucin-like protein (mlp) monoclonal antibodies, compositions and methods for detecting mlp as a biomarker for mucin-secreting type of cancer such as ovarian or pancreatic cancer.. . ... Omeros Corporation

Method of identifying transmembrane protein-interacting compounds

A method for screening compounds for their ability to interact with transmembrane proteins is provided. Also provided is a method for determining whether proteins such as transmembrane proteins are able to oligomerise.. ... Omeros Corporation

Methods for inhibiting fibrosis in a subject in need thereof

In one aspect, the invention provides methods for treating, inhibiting, alleviating or preventing fibrosis in a mammalian subject suffering, or at risk of developing a disease or disorder caused or exacerbated by fibrosis and/or inflammation. In one embodiment, the invention provides methods of treating a subject suffering from renal fibrosis. ... Omeros Corporation

Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same

In one aspect, the invention provides a method of making a bioactive peptide-bearing antibody, or fragment thereof, comprising (a) engrafting the amino acid sequence of at least one bioactive peptide of interest into (i) at least one of cdr-h1, cdr-h2 or cdr-h3 of a heavy chain variable region comprising one or more chicken framework regions and/or (ii) at least one of cdr-l1, cdr-l2 or cdr-l3 of the light chain variable region comprising one or more chicken framework regions, and (b) determining whether the antibody has substantially the same biological activity as the bioactive peptide.. . ... Omeros Corporation

Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation

A method and solution for perioperatively inhibiting a variety of pain and inflammation processes during arthroscopic procedures. The solution preferably includes a vasoconstrictor that demonstrates substantial agonist activity at alpha adrenergic receptors and that is selected for peripheral (local) vasoconstriction and one or more additional pain and inflammation inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated ringer's solution. ... Omeros Corporation

Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation

In one aspect, the invention provides methods of inhibiting the effects of masp-2-dependent complement activation in a living subject. In one embodiment, the invention provides methods of treating a subject suffering from a complement mediated coagulation disorder, such as disseminated intravascular coagulation. ... Omeros Corporation

Methods for treating conditions associated with masp-2 dependent complement activation

In one aspect, the invention provides methods of inhibiting the effects of masp-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a masp-2 inhibitory agent effective to inhibit masp-2-dependent complement activation. ... Omeros Corporation

Stable preservative-free mydriatic and anti-inflammatory solutions for injection

The present invention relates to stable, preservative- and antioxidant-free liquid formulations of phenylephrine and ketorolac for injection.. . ... Omeros Corporation

Methods for inhibiting fibrosis in a subject in need thereof

In one aspect, the invention provides methods for treating, inhibiting, alleviating or preventing fibrosis in a mammalian subject suffering, or at risk of developing a disease or disorder caused or exacerbated by fibrosis and/or inflammation. In one embodiment, the invention provides methods of treating a subject suffering from renal fibrosis. ... Omeros Corporation

07/06/17 / #20170188555

G protein coupled receptors and uses thereof

The present invention provides gpcr polypeptides and polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypeptides and polynucleotides are useful, for example, in methods of diagnosis and treatment of diseases and disorders. ... Omeros Corporation

06/29/17 / #20170182007

Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation

A method and solution for perioperatively inhibiting a variety of pain and inflammation processes during arthroscopic procedures. The solution preferably includes a vasoconstrictor that exhibits alpha- adrenergic activity and one or more additional pain and inflammation inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated ringer's solution. ... Omeros Corporation

06/15/17 / #20170166559

Solid state forms of a pde10 inhibitor

The invention relates to a novel variable hydrate crystalline form of 1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, methods for the preparation thereof, pharmaceutical compositions thereof and their use in the inhibition of pde10.. . ... Omeros Corporation

06/01/17 / #20170152238

Pde10 inhibitors and related compositions and methods

Compounds that inhibit pde10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as parkinson's disease, huntington's disease, alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, bell's palsy, cerebral palsy, sleep disorders, pain, tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided. ... Omeros Corporation

04/13/17 / #20170100412

Ophthalmologic irrigation solutions and method

Solutions for perioperative intraocular application by continuous irrigation during ophthalmologic procedures are provided. These solutions include multiple agents that act to inhibit inflammation, inhibit pain, effect mydriasis (dilation of the pupil), and/or decrease intraocular pressure, wherein the multiple agents are selected to target multiple molecular targets to achieve multiple differing physiologic functions, and are included in dilute concentrations in a balanced salt solution carrier.. ... Omeros Corporation

04/06/17 / #20170096420

Optically active pde10 inhibitor

The present invention is directed to a pure enantiomer of 1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, in particular, (s)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone. The present invention is also directed a crystal structure of (s)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, a pharmaceutical composition of (s)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, a method of inhibiting pde10 with (s)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, and a process and particular individual intermediates used in the production of (s)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone.. ... Omeros Corporation

03/30/17 / #20170088632

Compositions for inhibiting masp-2 dependent complement activation

The present invention relates to anti-masp-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of masp-2 dependent complement activation.. . ... Omeros Corporation

02/02/17 / #20170027920

Compositions and methods for prophylaxis and treatment of addictions

The present invention relates to methods of treating or preventing addiction and relapse use of addictive agents, and treating or preventing addictive or compulsive behaviour and relapse practice of an addictive behaviour or compulsion, by administering a peroxisome proliferator-activated receptor gamma (pparγ) agonist, alone or in combination with another therapeutic agent, such as, for example, an opioid receptor antagonist or an antidepressant, or an addictive agent, such as, for example, an opioid agonist. The present invention also includes pharmaceutical compositions for treating or preventing addiction or relapse that include a pparγ agonist and one or more other therapeutic or addictive agents, as well as unit dosage forms of such pharmaceutical compositions, which contain a dosage effective in treating or preventing addiction or relapse. ... Omeros Corporation

01/26/17 / #20170022190

Pde10 inhibitors and related compositions and methods

Isolated or pure compounds that inhibit pde10 are disclosed that have utility in the treatment of a variety of conditions, including but not limited to psychotic, anxiety, movement disorders and/or neurological disorders such as parkinson's disease, huntington's disease, alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, bell's palsy, cerebral palsy, sleep disorders, pain, tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided. ... Omeros Corporation








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Omeros Corporation in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Omeros Corporation with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###